The market value for monoclonal antibodies (mAbs) in colorectal cancer treatment is expected to reach $5.2 billion by 2019

The market value for monoclonal antibodies (mAbs) in colorectal cancer treatment will experience a moderate increase from $3.7 billion in 2012 to $5.2 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 5%.

The company’s report states that this moderate growth is due to the slow rise of the prevalent population and weakness of the late-stage pipeline. Currently, there is only one mAb product in Phase III development for the treatment of colorectal cancer, named IMC-1121B.

Analyst of this report says: “The efficacy of this drug has not yet been proven in large-scale, placebo-controlled 

Phase III trials, which creates an element of uncertainty in terms of the outcome of these products. As such, this weak late-stage pipeline is not expected to drive market growth to a significant extent during the forecast period.”

The current metastatic colorectal cancer market is dominated by three mAbs— Avastin, Erbitux and Vectibix — which are far more efficacious than the targeted small molecule therapies also marketed for this setting. Therefore, GBI Research believes there is a strong opportunity for the entry of new mAbs into the market, as long as they prove superior efficacy when compared to Avastin.

Analyst says: “A product that can attain first-line status in the treatment of colorectal cancer, or even second-line status by displacing Erbitux and Vectibix, would have access to a considerable patient population and be able to generate a substantial amount of revenue.

“Furthermore, there are currently no approved mAbs in the early-stage setting for colorectal cancer, reflecting an additional opportunity for the development of new products,” the analyst concludes.

This report provides in-depth analysis of three mAbs marketed for colorectal cancer, including analysis of their safety, efficacy, treatment patterns and strengths/weaknesses. It also gives a comprehensive review of the pipeline for colorectal cancer therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period.

For more information please visit: http://www.marketresearchreports.com/gbi-research/monoclonal-antibodies-market-colorectal-cancer-2019-favorable-pricing-policy-us-and

Browse other market research reports in diseases at http://www.marketresearchreports.com/diseases